Stryker stock outlook cut after Q3 growth misses expectations

Published on 11/10/2026 at 14:31 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Stryker stock remains under pressure after management lowered its 2026 outlook. Stronger adjusted margins and sales growth partly offset weaker reported earnings.

Quarterly Growth Meets Lower Guidance

Stryker delivered solid third-quarter sales growth, but management said performance fell short of expectations.
A goodwill impairment weighed on reported earnings while adjusted margins improved.
Management expects a solid fourth quarter and momentum heading into 2027.

Stryker Corp., US8636671013, Illustration mit AI erstellt.

Stryker stock traded at 289.90 euros on Lang & Schwarz at 14:30 CET on Tuesday, November 10, 2026. The medical-technology company is still being reassessed after its third-quarter update, which showed solid sales growth but fell short of management's expectations.

In a GlobeNewswire release carried by Yahoo Finance dated October 29, Stryker reported third-quarter net sales of 6.52 billion US dollars, up 7.7 percent from the prior-year period. Organic sales growth was also 7.7 percent. MedSurg and Neurotechnology increased sales by 9.2 percent, while Orthopaedics grew 5.7 percent.

Reported Earnings Under Pressure

Reported net earnings fell 12.3 percent to 753 million US dollars, and diluted earnings per share declined 11.7 percent to 1.96 US dollars. The figures included a 293 million US dollar goodwill impairment, which reduced reported profitability and made the headline earnings comparison less favorable.

Adjusted net earnings rose 10.1 percent to 1.4 billion US dollars. Adjusted diluted earnings per share increased 10.3 percent to 3.52 US dollars, while the adjusted operating margin widened by 60 basis points to 26.2 percent. The improvement in adjusted profitability provided support, but did not remove the concern that quarterly performance was below the company's internal target.

Guidance Reset Raises Execution Pressure

Stryker now expects organic net sales growth of 6.5 percent to 7.0 percent for 2026. The company previously targeted 8.3 percent to 9.3 percent. Adjusted diluted earnings per share are now expected at 14.80 to 14.90 US dollars, compared with the earlier range of 14.95 to 15.10 US dollars.

Chair and Chief Executive Kevin A. Lobo said the quarter delivered good overall performance and double-digit adjusted earnings growth, but fell short of expectations. He also pointed to a solid fourth quarter and good momentum heading into 2027. For investors, the lower targets shift attention from Stryker's underlying sales expansion to the pace at which joint-replacement demand and execution can recover.